Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

13 clinical trials · 13 recruiting · OTHER

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

RECRUITINGPhase 2NCT05443646

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

This study is a multi-center, Single-arm Phase II study to evaluate the clinical efficacy and safety of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 552 locations
Limited Stage Small Cell Lung Cancer
RECRUITINGPhase 2NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 4001 location
Malignancy
RECRUITINGNCT07352280

Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer

This study is a prospective, observational, real-world investigation. This study will evaluate the efficacy and safety of tislelizumab monotherapy before surgery in patients with...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 301 location
Colo-rectal Cancer (dMMR/MSI-H CRC)
RECRUITINGPhase 3NCT07443397

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

This study is a multicenter, randomized, prospective Phase III study to evaluate the efficacy and safety of anlotinib plus whole-brain radiotherapy (WBRT) compared with WBRT alone...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1341 location
Whole-Brain Radiotherapy
RECRUITINGPhase 3NCT06457906

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 3401 location
Small-cell Lung CancerBrain MetastasesSRS+3
RECRUITINGPhase 2NCT06087068

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and has a good prognosis.According to the 2015 American thyroid association (ATA) guidelines, no gross...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1401 location
Thyroid CancerSurgeryRecurrence
RECRUITINGNCT06277180

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 501 location
Medullary Thyroid CancerPrositron Emission TomographyFibroblast Activation Protein Inhibitor+1
RECRUITINGNCT02988921

MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or...

Magnetic resonance imaging (MRI) with functional features of diffusion weighted imaging (DWI) are advancing imaging technologies that have potential to overcome limitations of...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 3001 location
Esophagus CancerEsophagogastric Junction Cancer
RECRUITINGPhase 1 / Phase 2NCT04278287

Chemoradiotherapy in Unresectable Esophageal Cancer

This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1055 locations
Esophageal CancerChemoradiotherapyAlbumin-bound Paxlitaxel+1
RECRUITINGPhase 2NCT06410651

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 531 location
Esophageal CancerNimotuzumabChemoradiotherapy+2
RECRUITINGNCT06510543

Goal-directed Enteral Nutritional Perioperative Management

This clinical trial aims to determine whether perioperative goal-directed nutritional therapy can prevent postoperative pulmonary and other major complications in malnourished...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 40017 locations
Esophagus Cancer
RECRUITINGPhase 2NCT05188859

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 292 locations
Mesothelioma, MalignantMesothelioma, Malignant PleuralMesothelioma Malignant Advanced
RECRUITINGPhase 2NCT06543069

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 281 location
Malignant Peritoneal Mesothelioma, Advanced